J Drugs Dermatol. 2022 Jun 1;21(6):618-623. doi: 10.36849/JDD.6494.
Acne vulgaris is a multifactorial chronic disorder of the pilosebaceous unit. Established treatments include topical retinoids, antibiotics in mild cases, and oral antibiotics and isotretinoin in moderate to severe cases. Anti-androgens and other hormonal therapies constitute another group of drugs in the armamentarium of acne management. These can be used in patients who do not respond to the aforementioned treatments or when other systemic drugs cannot be tolerated. Recent approval of topical androgen receptor blocker is an additional armamentarium for the management of acne. Considering limited systemic exposure and good efficacy, it has potential for wide usage in patients with acne. In this article, we critically review currently available hormonal treatment options based on published literature search of an electronic database (MEDLINE/PubMed) performed through June 2021. J Drugs Dermatol. 2022;21(6):618-623. doi:10.36849/JDD.6494.
寻常痤疮是一种多因素的、累及毛囊皮脂腺单位的慢性疾病。已确立的治疗方法包括局部维 A 酸类药物、轻度病例的抗生素、中重度病例的口服抗生素和异维 A 酸。抗雄激素和其他激素疗法是痤疮治疗方案中的另一类药物。这些药物可用于对上述治疗方法无反应或不能耐受其他全身药物的患者。最近批准的局部雄激素受体阻滞剂是治疗痤疮的另一种手段。鉴于其系统暴露有限且疗效良好,它有可能在痤疮患者中广泛使用。本文基于 2021 年 6 月前电子数据库(MEDLINE/PubMed)的文献检索,对目前可用的激素治疗方案进行了批判性评价。J 皮肤病药物(J Drugs Dermatol)。2022;21(6):618-623. doi:10.36849/JDD.6494.